Functional structure of angiotensin-converting enzyme (ACE) and its targeted drugs

Abstract. Hypertension is a cardiovascular disease that is seriously harmful to human health. With the increase of age, the incidence of hypertension also increases sharply. Angiotensin-converting enzyme (ACE) is an enzyme that is closely related to hypertension in human body. As research on hypertension intensified, it became clear that ACE plays a role in influencing the balance of renin-angiotensin-aldosterone system. When there is too much ACE, the inactive angiotensin I in the renin-angiotensin-aldosterone system is over-converted to the active angiotensin II, and leads to a decrease in vaso-soothing substances such as bradykinin, which leads to abnormal increase in vasoconstriction pressure, leading to hypertension. ACE inhibitors (ACEIs) can effectively act on ACE. Since the introduction of captopril, there has been an endless stream of prilosec drugs developed for ACE, with more and more complicated indications. Therefore, this paper proposes a method for the development of drugs in a convenient way - molecular docking technology, using the combination condition of captopril and Drosophila ACE as an example, and discusses the effects of Benadryl on different hypertensive patients. We believe that ACE is a key protein in the treatment of hypertension, and hope that the study of ACE and ACEI and the proposed molecular docking technique in this paper will provide reference and ideas for future generations.